166 related articles for article (PubMed ID: 37958463)
21. [Treatment of non-testicular germ cell tumors in children and adolescents with BEP and VIP: initial results of the MAKEI 89 therapy study].
Göbel U; Bamberg M; Engert J; Gnekow AK; Haas HJ; Jürgens H; Kühl J; Lenard HG; Lumenta C; Niethammer D
Klin Padiatr; 1991; 203(4):236-45. PubMed ID: 1719267
[TBL] [Abstract][Full Text] [Related]
22. Death by bleomycin pulmonary toxicity in ovarian dysgerminoma with pathologic complete response to chemotherapy. A case report.
Calzas Rodríguez J; Carmen Juarez Morales MD; Casero MA
Respir Med Case Rep; 2016; 18():48-50. PubMed ID: 27330950
[TBL] [Abstract][Full Text] [Related]
23. Fertility outcomes following surgery and multiagent chemotherapy in malignant ovarian germ cell tumor survivors: a survey study.
Bergamini A; Ramaswami R; Froeling F; Papanastasopoulos P; Short D; Aguiar X; Savage PM; Sarwar N; Kaur B; Saso S; Fotopoulou C; Sharma A; Rustin GJS; Seckl M
Int J Gynecol Cancer; 2023 Nov; 33(11):1750-1756. PubMed ID: 37931975
[TBL] [Abstract][Full Text] [Related]
24. Adolescents and young adults with classical Hodgkin lymphoma in northern Tunisia: insights from an adult single-institutional study.
Zawati I; Adouni O; Finetti P; Manai M; Manai M; Gamoudi A; Birnbaum D; Bertucci F; Mezlini A
Cancer Radiother; 2020 Jun; 24(3):206-214. PubMed ID: 32171674
[TBL] [Abstract][Full Text] [Related]
25. "Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovarian tumors".
Gernier F; Ahmed-Lecheheb D; Pautier P; Floquet A; Nadeau C; Frank S; Alexandre J; Selle F; Berton-Rigaud D; Kalbacher E; Orfeuvre H; Lortholary A; Augereau P; Labombarda F; Perrier L; Grellard JM; Licaj I; Clarisse B; Savoye AM; Bourien H; De La Motte Rouge T; Kurtz JE; Kerdja K; Lelaidier A; Charreton A; Ray-Coquard I; Joly F
BMC Cancer; 2021 Oct; 21(1):1147. PubMed ID: 34702204
[TBL] [Abstract][Full Text] [Related]
26. Frequency and risk factors of bleomycin-induced pulmonary toxicity in South Indian patients with germ-cell tumors.
Thakkar DN; Ramasamy K; Adithan S; Selvarajan S; Dubashi B
J Cancer Res Ther; 2021; 17(2):443-449. PubMed ID: 34121690
[TBL] [Abstract][Full Text] [Related]
27. Outcome of 3-day bleomycin, etoposide and cisplatin chemotherapeutic regimen for patients with malignant ovarian germ cell tumours: a Taiwanese Gynecologic Oncology Group study.
Chen CA; Lin H; Weng CS; Wen KC; Lu CH; Chou HH; Huang YF; Kang CY; Ho CM; Yu MH; Chou CY
Eur J Cancer; 2014 Dec; 50(18):3161-7. PubMed ID: 25459394
[TBL] [Abstract][Full Text] [Related]
28. Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study.
Tryakin A; Fedyanin M; Kanagavel D; Fainstein I; Sergeev J; Polockij B; Matveev V; Zakharova T; Garin A; Tjulandin S
Urology; 2011 Sep; 78(3):620-5. PubMed ID: 21764427
[TBL] [Abstract][Full Text] [Related]
29. Experience of a 2-day BEP regimen in postsurgical adjuvant chemotherapy of ovarian germ cell tumors.
Tay SK; Tan LK
Int J Gynecol Cancer; 2000 Jan; 10(1):13-18. PubMed ID: 11240646
[TBL] [Abstract][Full Text] [Related]
30. Lowered Cisplatin Dose and No Bleomycin in the Treatment of Pediatric Germ Cell Tumors: Results of the GCT-99 Protocol From the Brazilian Germ Cell Pediatric Oncology Cooperative Group.
Lopes LF; Macedo CR; Aguiar Sdos S; Barreto JH; Martins GE; Sonaglio V; Milone M; Lima ER; Almeida MT; Lopes PM; Watanabe FM; D'Andrea ML; Pianovski MA; Melaragno R; Vianna SM; Moreira ME; Bruniera P; de Oliveira CZ
J Clin Oncol; 2016 Feb; 34(6):603-10. PubMed ID: 26729441
[TBL] [Abstract][Full Text] [Related]
31. The effect of cisplatin dose and surgical resection in children with malignant germ cell tumors at the sacrococcygeal region: a pediatric intergroup trial (POG 9049/CCG 8882).
Rescorla F; Billmire D; Stolar C; Vinocur C; Colombani P; Cullen J; Giller R; Cushing B; Lauer S; Davis M; Hawkins E; Shuster J; Krailo M
J Pediatr Surg; 2001 Jan; 36(1):12-7. PubMed ID: 11150431
[TBL] [Abstract][Full Text] [Related]
32. Bleomycin, etoposide and cisplatinum (BEP) chemotherapy for metastatic germ cell tumours: treatment outcomes at UKM medical centre, Malaysia.
Azrif M; Leong YK; Aslan NM; Fong KV; Ismail F
Asian Pac J Cancer Prev; 2012; 13(6):2467-71. PubMed ID: 22938405
[TBL] [Abstract][Full Text] [Related]
33. Germ cell tumors of the ovary.
Pectasides D; Pectasides E; Kassanos D
Cancer Treat Rev; 2008 Aug; 34(5):427-41. PubMed ID: 18378402
[TBL] [Abstract][Full Text] [Related]
34. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.
Motzer RJ; Nichols CJ; Margolin KA; Bacik J; Richardson PG; Vogelzang NJ; Bajorin DF; Lara PN; Einhorn L; Mazumdar M; Bosl GJ
J Clin Oncol; 2007 Jan; 25(3):247-56. PubMed ID: 17235042
[TBL] [Abstract][Full Text] [Related]
35. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
Culine S; Kramar A; Théodore C; Geoffrois L; Chevreau C; Biron P; Nguyen BB; Héron JF; Kerbrat P; Caty A; Delva R; Fargeot P; Fizazi K; Bouzy J; Droz JP;
J Clin Oncol; 2008 Jan; 26(3):421-7. PubMed ID: 18202419
[TBL] [Abstract][Full Text] [Related]
36. Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network.
Derquin F; Floquet A; Hardy-Bessard AC; Edeline J; Lotz JP; Alexandre J; Pautier P; Angeles MA; Delanoy N; Lefeuvre-Plesse C; Cancel M; Treilleux I; Augereau P; Lavoue V; Kalbacher E; Berton Rigaud D; Selle F; Nadeau C; Gantzer J; Joly F; Guillemet C; Pomel C; Favier L; Abdeddaim C; Venat-Bouvet L; Provansal M; Fabbro M; Kaminsky MC; Lortholary A; Lecuru F; Coquard IR; de La Motte Rouge T
Gynecol Oncol; 2020 Sep; 158(3):666-672. PubMed ID: 32624235
[TBL] [Abstract][Full Text] [Related]
37. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial.
Hinton S; Catalano PJ; Einhorn LH; Nichols CR; David Crawford E; Vogelzang N; Trump D; Loehrer PJ
Cancer; 2003 Apr; 97(8):1869-75. PubMed ID: 12673712
[TBL] [Abstract][Full Text] [Related]
38. The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity.
Mann JR; Raafat F; Robinson K; Imeson J; Gornall P; Sokal M; Gray E; McKeever P; Hale J; Bailey S; Oakhill A
J Clin Oncol; 2000 Nov; 18(22):3809-18. PubMed ID: 11078494
[TBL] [Abstract][Full Text] [Related]
39. Pilot study of cisplatin, etoposide, bleomycin, and escalating dose cyclophosphamide therapy for children with high risk germ cell tumors: a report of the children's oncology group (COG).
Malogolowkin MH; Krailo M; Marina N; Olson T; Frazier AL
Pediatr Blood Cancer; 2013 Oct; 60(10):1602-5. PubMed ID: 23703725
[TBL] [Abstract][Full Text] [Related]
40. Outcomes of Surgery Alone and Surveillance Strategy in Young Women With Stage I Malignant Ovarian Germ Cell Tumors.
Park JY; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
Int J Gynecol Cancer; 2016 Jun; 26(5):859-64. PubMed ID: 27101582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
